These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19702528)

  • 1. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.
    Di YM; Chow VD; Yang LP; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):754-80. PubMed ID: 19702528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
    Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
    Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
    Nakajima M; Kuroiwa Y; Yokoi T
    Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
    Zhou SF; Wang B; Yang LP; Liu JP
    Drug Metab Rev; 2010 May; 42(2):268-354. PubMed ID: 19961320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen.
    Yano JK; Hsu MH; Griffin KJ; Stout CD; Johnson EF
    Nat Struct Mol Biol; 2005 Sep; 12(9):822-3. PubMed ID: 16086027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2A6: genetics, structure, regulation, and function.
    Raunio H; Rahnasto-Rilla M
    Drug Metabol Drug Interact; 2012 May; 27(2):73-88. PubMed ID: 22706231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
    Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
    Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.
    Le Gal A; Dréano Y; Lucas D; Berthou F
    Toxicol Lett; 2003 Sep; 144(1):77-91. PubMed ID: 12919726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
    Oscarson M
    Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
    Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
    Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression.
    Wang J; Pitarque M; Ingelman-Sundberg M
    Biochem Biophys Res Commun; 2006 Feb; 340(2):491-7. PubMed ID: 16378601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.
    Lai XS; Yang LP; Li XT; Liu JP; Zhou ZW; Zhou SF
    Curr Drug Metab; 2009 Nov; 10(9):1009-47. PubMed ID: 20214592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
    Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF
    Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and environmental influences on therapeutic and toxicity outcomes: studies with CYP2A6.
    Satarug S; Tassaneeyakul W; Na-Bangchang K; Cashman JR; Moore MR
    Curr Clin Pharmacol; 2006 Sep; 1(3):291-309. PubMed ID: 18666753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2A6 genetic variation and potential consequences.
    Xu C; Goodz S; Sellers EM; Tyndale RF
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1245-56. PubMed ID: 12406643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
    Mwenifumbo JC; Tyndale RF
    Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key residues controlling binding of diverse ligands to human cytochrome P450 2A enzymes.
    DeVore NM; Smith BD; Wang JL; Lushington GH; Scott EE
    Drug Metab Dispos; 2009 Jun; 37(6):1319-27. PubMed ID: 19251817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
    Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of heterogeneous nuclear ribonucleoprotein A1 with cytochrome P450 2A6 mRNA: implications for post-transcriptional regulation of the CYP2A6 gene.
    Christian K; Lang M; Maurel P; Raffalli-Mathieu F
    Mol Pharmacol; 2004 Jun; 65(6):1405-14. PubMed ID: 15155834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel human CYP2A6 alleles confound gene deletion analysis.
    Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T
    FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.